CSF VILIP-1 predicts rates of cognitive decline in early Alzheimer disease.

Neurology
Rawan TarawnehDavid M Holtzman

Abstract

Measures of neuronal damage/dysfunction are likely good surrogates for disease progression in Alzheimer disease (AD). CSF markers of neuronal injury may offer utility in predicting disease progression and guiding prognostic and outcome assessments in therapeutic trials. Visinin-like protein-1 (VILIP-1) has demonstrated potential utility as a marker of neuronal injury. We here investigate the utility of VILIP-1 and VILIP-1/Aβ42 in predicting rates of cognitive decline in early AD. Individuals with a clinical diagnosis of very mild or mild AD (n = 60) and baseline CSF measures of VILIP-1, tau, p-tau181, and Aβ42 were followed longitudinally for an average of 2.6 years. Annual assessments included the Clinical Dementia Rating (CDR), CDR-sum of boxes (CDR-SB), and global composite scores. Mixed linear models assessed the ability of CSF biomarker measures to predict rates of cognitive decline over time. Baseline CSF VILIP-1 and VILIP-1/Aβ42 levels predicted rates of future decline in CDR-SB and global composite scores over the follow-up period. Individuals with CSF VILIP-1 ≥560 pg/mL (corresponding to the upper tercile) progressed much more rapidly in CDR-SB (1.61 boxes/year; p = 0.0077) and global scores (-0.53 points/year; p = 0.0...Continue Reading

References

Jun 1, 1988·Neurology·E GroberR Dresner
Mar 11, 1999·Annals of Neurology·J L Price, J C Morris
Apr 13, 2001·Current Opinion in Neurobiology·A Martin, L L Chao
Apr 17, 2001·The Behavioral and Brain Sciences·J P Aggleton, M W Brown
Sep 18, 2001·Archives of Neurology·J L PriceJ C Morris
Jun 14, 2005·Neuropsychologia·R B DudasJ R Hodges
Jul 22, 2006·Clinical Chemistry·Omar F LaterzaJack H Ladenson
Nov 30, 2006·Alzheimer Disease and Associated Disorders·John C MorrisWalter A Kukull
May 8, 2007·Neuroscience Letters·Kaj BlennowNiels Andreasen
Jul 29, 2009·Neurology·P VemuriUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Oct 14, 2009·Archives of Neurology·David K JohnsonJames E Galvin
Oct 28, 2009·Neurology·M I KesterW M van der Flier
Jan 20, 2010·Lancet Neurology·Clifford R JackJohn Q Trojanowski
Sep 3, 2010·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Kaori ItoUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Aug 9, 2011·Annals of Neurology·Rawan TarawnehDavid M Holtzman

❮ Previous
Next ❯

Citations

Jan 16, 2013·PloS One·Julien DumurgierUNKNOWN Groupe d’Investigation du Liquide Cephalorachidien (GIL) Study Network
Aug 25, 2012·Biomarkers in Medicine·Anne M Fagan, Richard J Perrin
Jun 3, 2014·Current Genetic Medicine Reports·Mary Ann A DeMichele-Sweet, Robert A Sweet
Apr 16, 2014·Neuroscience Bulletin·Xiaojing SuiXifei Yang
Jan 10, 2013·The Journal of Nutrition, Health & Aging·H Hampel, S Lista
May 9, 2015·Brain Injury : [BI]·Pashtun ShahimYelverton Tegner
Jan 13, 2016·Journal of Alzheimer's Disease : JAD·Tomasz DziedzicAgnieszka Slowik
Jan 16, 2016·Journal of Neuropathology and Experimental Neurology·Caitlin M KirkwoodRobert A Sweet
Oct 8, 2013·Clinics in Geriatric Medicine·Meredith Wicklund, Ronald C Petersen
Oct 10, 2013·Biological Psychiatry·Patrick S MurrayRobert A Sweet
Sep 10, 2013·Biological Psychiatry·Courtney L SutphenDavid M Holtzman
May 31, 2016·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Niklas MattssonEnchi Liu
Jul 4, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Harald HampelZaven S Khachaturian
Sep 18, 2015·Frontiers in Neurology·Aaron Ritter, Jeffrey Cummings
Feb 11, 2015·Clinica Chimica Acta; International Journal of Clinical Chemistry·Kina HöglundErik Portelius
Jun 4, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·David PetersonUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Sep 25, 2015·Journal of Alzheimer's Disease : JAD·Magdalena GroblewskaBarbara Mroczko
Mar 17, 2015·European Journal of Pharmacology·Saeed Sadigh-EteghadShirin Babri
Oct 16, 2016·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Scott E CountsElliott J Mufson
Jun 26, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Oskar HanssonKaj Blennow
Mar 28, 2018·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Courtney L SutphenUNKNOWN ADNI
Dec 18, 2016·Clinical Chemistry·Daniel L CrimminsJack H Ladenson
Sep 9, 2016·Molecular Neurodegeneration·Claudia CicognolaKaj Blennow
Oct 27, 2017·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Camilla Steen JensenAnja Hviid Simonsen
Nov 30, 2018·Acta Neuropathologica·José Luis MolinuevoKaj Blennow
Jan 4, 2020·Therapeutic Advances in Neurological Disorders·Marta Milà-AlomàJosé Luís Molinuevo
Apr 5, 2017·Frontiers in Neurology·Rose Ann Huynh, Chandra Mohan
Oct 13, 2017·Translational Neurodegeneration·Jeffrey Cummings
Oct 13, 2018·Translational Neurodegeneration·Hua ZhangUNKNOWN Alzheimer’s Disease Neuroimaging Initiative

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.